Search

Your search keyword '"Schlenk, R.F."' showing total 49 results
Start Over Author "Schlenk, R.F."
49 results on '"Schlenk, R.F."'

1. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial

Author

Heilig, C.E., Horak, P., Kreutzfeldt, S., Teleanu, V., Mock, A., Renner, M., Bhatti, I.A., Hutter, B., Hüllein, J., Fröhlich, M., Uhrig, S., Süße, H., Heiligenthal, L., Ochsenreither, S., Illert, A.L., Vogel, A., Desuki, A., Heinemann, V., Heidegger, S., Bitzer, M., Scheytt, M., Brors, B., Hübschmann, D., Baretton, G., Stenzinger, A., Steindorf, K., Benner, A., Jäger, D., Heining, C., Glimm, H., Fröhling, S., and Schlenk, R.F.

Published
2021
Full Text
View/download PDF

3. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers

Author

Jahn, A., primary, Rump, A., additional, Widmann, T.J., additional, Heining, C., additional, Horak, P., additional, Hutter, B., additional, Paramasivam, N., additional, Uhrig, S., additional, Gieldon, L., additional, Drukewitz, S., additional, Kübler, A., additional, Bermudez, M., additional, Hackmann, K., additional, Porrmann, J., additional, Wagner, J., additional, Arlt, M., additional, Franke, M., additional, Fischer, J., additional, Kowalzyk, Z., additional, William, D., additional, Weth, V., additional, Oster, S., additional, Fröhlich, M., additional, Hüllein, J., additional, Valle González, C., additional, Kreutzfeldt, S., additional, Mock, A., additional, Heilig, C.E., additional, Lipka, D.B., additional, Möhrmann, L., additional, Hanf, D., additional, Oleś, M., additional, Teleanu, V., additional, Allgäuer, M., additional, Ruhnke, L., additional, Kutz, O., additional, Knurr, A., additional, Laßmann, A., additional, Endris, V., additional, Neumann, O., additional, Penzel, R., additional, Beck, K., additional, Richter, D., additional, Winter, U., additional, Wolf, S., additional, Pfütze, K., additional, Geörg, C., additional, Meißburger, B., additional, Buchhalter, I., additional, Augustin, M., additional, Aulitzky, W.E., additional, Hohenberger, P., additional, Kroiss, M., additional, Schirmacher, P., additional, Schlenk, R.F., additional, Keilholz, U., additional, Klauschen, F., additional, Folprecht, G., additional, Bauer, S., additional, Siveke, J.T., additional, Brandts, C.H., additional, Kindler, T., additional, Boerries, M., additional, Illert, A.L., additional, von Bubnoff, N., additional, Jost, P.J., additional, Metzeler, K.H., additional, Bitzer, M., additional, Schulze-Osthoff, K., additional, von Kalle, C., additional, Brors, B., additional, Stenzinger, A., additional, Weichert, W., additional, Hübschmann, D., additional, Fröhling, S., additional, Glimm, H., additional, Schröck, E., additional, and Klink, B., additional

Published
2022
Full Text
View/download PDF

4. 1490MO CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)

Author

Teleanu, M-V., primary, Heilig, C.E., additional, Hamacher, R.W., additional, Bauer, S., additional, Mayer-Steinacker, R., additional, Gaidzik, V.I., additional, Horak, P., additional, Lanz, L-M., additional, Muskatewitz, T., additional, Süsse, H., additional, Freitag, A., additional, von Hornung, M., additional, Wacker, L., additional, Von Kalle, C., additional, Barth, T., additional, Fröhling, S., additional, and Schlenk, R.F., additional

Published
2022
Full Text
View/download PDF

5. 487P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies

Author

Heilig, C.E., primary, Teleanu, M-V., additional, Bhatti, I.A., additional, Richter, S., additional, Siveke, J.T., additional, Wagner, S., additional, Kopp, H-G., additional, Kindler, T., additional, Illert, L., additional, Golf, A., additional, Dormann, K., additional, Benner, A., additional, Süsse, H., additional, Freitag, A., additional, Von Kalle, C., additional, Glimm, H., additional, Hübschmann, D., additional, Fröhling, S., additional, and Schlenk, R.F., additional

Published
2022
Full Text
View/download PDF

7. 196P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies

Author

Schlenk, R.F., Rübsam, M., Teleanu, M-V., Richter, S., Siveke, J.T., Wagner, S., Kopp, H-G., Kindler, T., Illert, L., Golf, A.H-E., Dorman, K., Schreck, N., Benner, A., Süsse, H., Freitag, A., von Kalle, C., Glimm, H., Hübschmann, D., Fröhling, S., and Heilig, C.E.

Published
2024
Full Text
View/download PDF

10. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Author

Larson, R.A., Mandrekar, S.J., Huebner, L.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Döhner, K., Marcucci, G., Voso, M.T., Klisovic, R.B., Galinsky, I., Wei, A.H., Sierra, J., Sanz, Mariano, Brandwein, J.M., Witte, T.J. de, Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Krauter, J., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Döhner, H., Stone, R.M., Larson, R.A., Mandrekar, S.J., Huebner, L.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Döhner, K., Marcucci, G., Voso, M.T., Klisovic, R.B., Galinsky, I., Wei, A.H., Sierra, J., Sanz, Mariano, Brandwein, J.M., Witte, T.J. de, Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Krauter, J., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Döhner, H., and Stone, R.M.

Abstract

Item does not contain fulltext, The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance) demonstrated a statistically significant overall survival benefit from the addition of midostaurin to standard frontline chemotherapy in a genotypically-defined subgroup of 717 patients with FLT3-mutant acute myeloid leukemia (AML). The risk of death was reduced by 22% on the midostaurin-containing arm. In this post hoc analysis, we analyzed the cumulative incidence of relapse (CIR) on this study and also evaluated the impact of 12 4-week cycles of maintenance therapy. CIR analyses treated relapses and AML deaths as events, deaths from other causes as competing risks, and survivors in remission were censored. CIR was improved on the midostaurin arm (HR = 0.71 (95% CI, 0.54-0.93); p = 0.01), both overall and within European LeukemiaNet 2017 risk classification subsets when post-transplant events were considered in the analysis as events. However, when transplantation was considered as a competing risk, there was overall no significant difference between the risks of relapse on the two randomized arms. Patients still in remission after consolidation with high-dose cytarabine entered the maintenance phase, continuing with either midostaurin or placebo. Analyses were inconclusive in quantifying the impact of the maintenance phase on the overall outcome. In summary, midostaurin reduces the CIR.

Published
2021

16. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: Results complement1 from the pivotal phase III study

Author

Tausch, E. Beck, P. Schlenk, R.F. Jebaraj, B.M.C. Dolnik, A. Yosifov, D.Y. Hillmen, P. Offner, F. Janssens, A. Govind Babu, K. Grosicki, S. Mayer, J. Panagiotidis, P. McKeown, A. Gupta, I.V. Skorupa, A. Pallaud, C. Bullinger, L. Mertens, D. Döhner, H. Stilgenbauer, S.

Abstract

Next generation sequencing studies in chronic lymphocytic leukemia (CLL) have revealed novel genetic variants that have been associated with disease characteristics and outcome. The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL. Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial [treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL)]. Baseline samples were available from 383 patients (85.6%) representative of the total trial cohort. Mutations were analyzed by amplicon-based targeted next generation sequencing (tNGS). In 52.2% of patients we found at least one mutation; the incidence was highest in NOTCH1 (17.0%), followed by SF3B1 (14.1%), ATM (11.7%), TP53 (10.2%), POT1 (7.0%), RPS15 (4.4%), FBXW7 (3.4%), MYD88 (2.6%), and BIRC3 (2.3%). While most mutations lacked prognostic significance, TP53 (HR2.02, P

Published
2020

17. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Author

Dohner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R.A., Prior, T.W., Marcucci, G., Jones, Dan, Krauter, J., Heuser, M., Voso, M.T., Ottone, T., Nomdedeu, J.F., Mandrekar, S.J., Klisovic, R.B., Wei, A.H., Sierra, J., Sanz, Mariano, Brandwein, J.M., Witte, T.J. de, Jansen, J.H., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Benner, A., Pallaud, C., Stone, R.M., Dohner, H., Bloomfield, C.D., Dohner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R.A., Prior, T.W., Marcucci, G., Jones, Dan, Krauter, J., Heuser, M., Voso, M.T., Ottone, T., Nomdedeu, J.F., Mandrekar, S.J., Klisovic, R.B., Wei, A.H., Sierra, J., Sanz, Mariano, Brandwein, J.M., Witte, T.J. de, Jansen, J.H., Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Benner, A., Pallaud, C., Stone, R.M., Dohner, H., and Bloomfield, C.D.

Abstract

Contains fulltext : 218279.pdf (Publisher’s version ) (Open Access), Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (>/=0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 NPM1/FLT3-ITD genotypes differed significantly with regard to clinical and concurrent genetic features. Complete ELN risk categorization could be done in 318 of 549 trial patients with FLT3-ITD AML. Significant factors for response after 1 or 2 induction cycles were ELN risk group and white blood cell (WBC) counts; treatment with midostaurin had no influence. Overall survival (OS) differed significantly among ELN risk groups, with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-, intermediate-, and adverse-risk groups, respectively (P < .001). A multivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in first complete remission as a time-dependent variable revealed treatment with midostaurin, allogeneic HCT, ELN favorable-risk group, and lower WBC counts as significant favorable factors. In this model, there was a consistent beneficial effect of midostaurin across ELN risk groups.

Published
2020

18. Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium

Author

Horak, P., primary, Kreutzfeldt, S., additional, Mock, A., additional, Heining, C., additional, Heilig, C.E., additional, Möhrmann, L., additional, Uhrig, S., additional, Hübschmann, D., additional, Beck, K., additional, Richter, D., additional, Schlenk, R.F., additional, Klink, B., additional, Hutter, B., additional, Weichert, W., additional, Stenzinger, A., additional, Schröck, E., additional, Brors, B., additional, Glimm, H., additional, and Fröhling, S., additional

Published
2019
Full Text
View/download PDF

19. NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib

Author

Goto, Y., primary, Cadranel, J., additional, Weinberg, B.A., additional, Duruisseaux, M., additional, Liu, S.V., additional, Tolba, K., additional, Branden, E., additional, Doebele, R.C., additional, Heining, C., additional, Schlenk, R.F., additional, Laskin, J.J., additional, Cheema, P.K., additional, Jones, M.R., additional, Trombetta, D., additional, Muscarella, L.A., additional, Cseh, A., additional, Solca, F., additional, and Renouf, D.J., additional

Published
2019
Full Text
View/download PDF

21. Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Author

Liu, S.V., primary, Duruisseaux, M., additional, Tolba, K., additional, Branden, E., additional, Goto, Y., additional, Weinberg, B.A., additional, Renouf, D.J., additional, Doebele, R.C., additional, Heining, C., additional, Schlenk, R.F., additional, Cheema, P.K., additional, Cadranel, J., additional, Jones, M.R., additional, Drilon, A.E., additional, Trombetta, D., additional, Muscarella, L.A., additional, Cseh, A., additional, Solca, F., additional, and Laskin, J.J., additional

Published
2019
Full Text
View/download PDF

22. Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies

Author

Heilig, C.E., primary, Hübschmann, D., additional, Kopp, H.-G., additional, Metzeler, K.H., additional, Richter, S., additional, Hermes, B., additional, von Bubnoff, N., additional, Kindler, T., additional, Siveke, J., additional, Wagner, S., additional, Ochsenreither, S., additional, Süße, H., additional, Brors, B., additional, Benner, A., additional, Jäger, D., additional, Von Kalle, C., additional, Glimm, H., additional, Gröschel, S., additional, Fröhling, S., additional, and Schlenk, R.F., additional

Published
2019
Full Text
View/download PDF

23. PS1033 A PROOF OF CONCEPT OF LSD1-INHIBITON IN A PHASE I/II PILOT TRIAL OF TCP AND ATRA IN REFRACTORY / RELAPSED AML PATIENTS NOT ELIGIBLE FOR INTENSIVE THERAPY

Author

Wass, M., primary, Schlenk, R.F., additional, Göthert, J., additional, Noppeney, R., additional, Schliemann, C., additional, Mikesch, J.-H., additional, Dugas, M., additional, Wermke, M., additional, Röllig, C., additional, Bornhäuser, M., additional, Serve, H., additional, Binder, M., additional, Müller, L.P., additional, Göllner, S., additional, Pabst, C., additional, and Müller-Tidow, C., additional

Published
2019
Full Text
View/download PDF

24. PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY

Author

Voso, M.T., primary, Larson, R.A., additional, Prior, T., additional, Marcucci, G., additional, Jones, D., additional, Krauter, J., additional, Heuser, M., additional, Lavorgna, S., additional, Nomdedeu, J., additional, Geyer, S.M., additional, Klisovic, R., additional, Wei, A.H., additional, Sierra, J., additional, Sanz, M.A., additional, Brandwein, J.M., additional, de Witte, T.M., additional, Jansen, J.H., additional, Niederweiser, D., additional, Appelbaum, F.R., additional, Medeiros, B.C., additional, Tallman, M.S., additional, Schlenk, R.F., additional, Ganser, A., additional, Amadori, S., additional, Cheng, Y., additional, Chen, Y., additional, Tiecke, E., additional, Du, L., additional, Ehninger, G., additional, Thiede, C., additional, Döhner, K., additional, Döhner, H., additional, Stone, R.M., additional, Bloomfield, C.D., additional, and Lo-Coco, F., additional

Published
2019
Full Text
View/download PDF

25. S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG)

Author

Rücker, F.G., primary, Agrawal, M., additional, Corbacioglu, A., additional, Weber, D., additional, Kapp-Schwoerer, S., additional, Gaidzik, V.I., additional, Jahn, N., additional, Schroeder, T., additional, Wattad, M., additional, Lübbert, M., additional, Koller, E., additional, Kindler, T., additional, Götze, K., additional, Ringhoffer, M., additional, Westermann, J., additional, Fiedler, W., additional, Horst, H.A., additional, Greil, R., additional, Schroers, R., additional, Mayer, K., additional, Heinicke, T., additional, Krauter, J., additional, Schlenk, R.F., additional, Thol, F., additional, Heuser, M., additional, Ganser, A., additional, Bullinger, L., additional, Paschka, P., additional, Döhner, H., additional, and Döhner, K., additional

Published
2019
Full Text
View/download PDF

26. PS1035 GEMTUZUMAB OZOGAMICINE-BASED SALVAGE THERAPIES IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS

Author

Segura, S. Jaramillo, primary, Montesinos, P., additional, Venditti, A., additional, Papayannidis, C., additional, Kayser, S., additional, Martinez-cuadrón, D., additional, Paterno, G., additional, Serrano, J., additional, Polo, M., additional, García-Boyero, R., additional, Müller-Tidow, C., additional, and Schlenk, R.F., additional

Published
2019
Full Text
View/download PDF

27. PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY

Author

Döhner, K., primary, Thiede, C., additional, Jahn, N., additional, Ekaterina, P., additional, Gambietz, A., additional, Prior, T.W., additional, Marcucci, G., additional, Jones, D., additional, Krauter, J., additional, Michael, H., additional, Lo-Coco, F., additional, Ottone, T., additional, Nomdedeu, J., additional, Mandrekar, S.J., additional, Huebner, L., additional, Laumann, K.M., additional, Geyer, S.M., additional, Klisovic, R.B., additional, Wei, A., additional, Sierra, J., additional, Sanz, M.A., additional, Brandwein, J.M., additional, de Witte, T.M., additional, Jansen, J.H., additional, Niederwieser, D., additional, Appelbaum, F.R., additional, Medeiros, B.C., additional, Tallman, M.S., additional, Schlenk, R.F., additional, Ganser, A., additional, Serve, H., additional, Ehninger, G., additional, Amadori, S., additional, Gathmann, I., additional, Axel, B., additional, Pallaud, C., additional, Larson, R.A., additional, Stone, R.M., additional, Döhner, H., additional, and Bloomfield, C.D., additional

Published
2019
Full Text
View/download PDF

28. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Author

Stone, R.M., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Dohner, K., Marcucci, G., Lo-Coco, F., Klisovic, R.B., Wei, A., Sierra, J., Sanz, M.A., Brandwein, J.M., Witte, T.J. de, Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Krauter, J., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Larson, R.A., Dohner, H., Stone, R.M., Mandrekar, S.J., Sanford, B.L., Laumann, K., Geyer, S., Bloomfield, C.D., Thiede, C., Prior, T.W., Dohner, K., Marcucci, G., Lo-Coco, F., Klisovic, R.B., Wei, A., Sierra, J., Sanz, M.A., Brandwein, J.M., Witte, T.J. de, Niederwieser, D., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Krauter, J., Schlenk, R.F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Larson, R.A., and Dohner, H.

Abstract

Item does not contain fulltext, BACKGROUND: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would prolong overall survival in this population. METHODS: We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 mutations. Patients were randomly assigned to receive standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or placebo. Randomization was stratified according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal tandem duplication (ITD) mutation with either a high ratio (>0.7) or a low ratio (0.05 to 0.7) of mutant to wild-type alleles (ITD [high] and ITD [low], respectively). Allogeneic transplantation was allowed. The primary end point was overall survival. RESULTS: A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 357 to the placebo group. The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, and TKD in 162 patients. The treatment groups were well balanced with respect to age, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin group vs. 59.4% in the placebo group were women, P=0.04). Overall survival was significantly longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P=0.009), as was event-free survival (hazard ratio for event or death, 0.78; one-sided P=0.002). In both the primary analysis and an analysis in which data for patients who underwent transplantation were censored, the benefit of mi

Published
2017

29. Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia

Author

Hirsch, S. (Susanne), Blätte, T.J. (Tamara J.), Grasedieck, S. (Sarah), Cocciardi, S. (Sibylle), Rouhi, A. (Arefeh), Jongen-Lavrencic, M. (Mojca), Paschka, P. (Peter), Krönke, J. (Jan), Gaidzik, V.I. (Verena), Döhner, H. (Hartmut), Schlenk, R.F. (Richard), Kuchenbauer, F. (Florian), Döhner, K. (Konstanze), Dolnik, A. (Anna), Bullinger, L. (Lars), Hirsch, S. (Susanne), Blätte, T.J. (Tamara J.), Grasedieck, S. (Sarah), Cocciardi, S. (Sibylle), Rouhi, A. (Arefeh), Jongen-Lavrencic, M. (Mojca), Paschka, P. (Peter), Krönke, J. (Jan), Gaidzik, V.I. (Verena), Döhner, H. (Hartmut), Schlenk, R.F. (Richard), Kuchenbauer, F. (Florian), Döhner, K. (Konstanze), Dolnik, A. (Anna), and Bullinger, L. (Lars)

Abstract

In acute myeloid leukemia, there is growing evidence for splicing pattern deregulation, including differential expression of linear splice isoforms of the commonly mutated gene nucleophosmin (NPM1). In this study, we detect circular RNAs of NPM1 and quantify circRNA hsa_circ_0075001 in a cohort of NPM1 wild-type and mutated acute myeloid leukemia (n=46). Hsa_circ_0075001 expression correlates positively with total NPM1 expression, but is independent of the NPM1 mutational status. High versus low hsa_circ_0075001 expression defines patient subgroups characterized by distinct gene expression patterns, such as lower expression of components of the Toll-like receptor signaling pathway in high hsa_circ_0075001 expression cases. Global evaluation of circRNA expression in sorted healthy hematopoietic controls (n=10) and acute myeloid leukemia (n=10) reveals circRNA transcripts for 47.9% of all highly expressed genes. While circRNA expression correlates globally with parental gene expression, we identify hematopoietic differentiation-associated as well as acute myeloid leukemia subgroup-specific circRNA signatures.

Published
2017
Full Text
View/download PDF

33. 1979TiP - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies

Author

Heilig, C.E., Hübschmann, D., Kopp, H.-G., Metzeler, K.H., Richter, S., Hermes, B., von Bubnoff, N., Kindler, T., Siveke, J., Wagner, S., Ochsenreither, S., Süße, H., Brors, B., Benner, A., Jäger, D., Von Kalle, C., Glimm, H., Gröschel, S., Fröhling, S., and Schlenk, R.F.

Published
2019
Full Text
View/download PDF

35. SUCCESSFUL HIGH DOSE CHEMOTHERAPY (HDC) WITH AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION (SCT) IN TWO PATIENTS WITH BEHCET'S DISEASE AND PULMONARY INVOLVEMENT

Author

Hensel, M., Schlenk, R.F., Fiehn, C., Breitbart, A., and Ho, A.D.

Subjects
Behcet's disease -- Care and treatment, Hematopoietic stem cells -- Transplantation, Health, Care and treatment
Abstract

Background: The prognosis of patients with Behcet's disease and pulmonary involvement is poor. Half of the patients die within three years after the onset of haemoptysis. Patients: We describe the [...]

Published
2001

36. 120 RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)

Author

Schuler, E., primary, Schemenau, J., additional, Giagounidis, A., additional, Haase, D., additional, Büsche, G., additional, Platzbecker, U., additional, Nolte, F., additional, Götze, K., additional, Schlenk, R.F., additional, Ganser, A., additional, Letsch, A., additional, Lübbert, M., additional, Schafhausen, P., additional, Bug, G., additional, and Germing, U., additional

Published
2015
Full Text
View/download PDF

37. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,515 cases of AML

Author

Groschel, S., Lugthart, S., Beverloo, B.H., Kayser, S., Valk, P.J., Van Zelderen-Bhola, S.L., Ossenkoppele, G.J., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., Verhoef, G., Ferrant, A, Kohne, C.H., Pfreundschuh, M., Horst, H.A., Koller, E., von Lilienfeld-Toal, M., Bentz, M., Ganser, A., Schlegelberger, B., Jotterand, M., Krauter, J., Pabst, T., Theobald, M, Schlenk, R.F., Delwel, R., Dohner, K., Lowenberg, B., Dohner, H., Hematology, and CCA - Innovative therapy

Published
2010

38. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA

Author

Schlenk, R.F. (Richard), Taskesen, E. (Erdogan), Norden, Y. (Yvette) van, Krauter, J., Ganser, A. (Arnold), Bullinger, L. (Lars), Gaidzik, V.I. (Verena), Paschka, P. (Peter), Corbacioglu, A. (Andrea), Göhring, G. (Gudrun), Kündgen, A. (Andrea), Held, G. (Gerhard), Götze, T. (Tobias), Vellenga, E. (Edo), Kuball, J. (Jürgen), Schanz, U. (Urs), Passweg, J. (Jakob Robert), Pabst, T. (Thomas), Maertens, J. (Johan), Ossenkoppele, G.J. (Gert), Delwel, H.R. (Ruud), Döhner, H. (Hartmut), Cornelissen, J.J. (Jan), Döhner, K. (Konstanze), Löwenberg, B. (Bob), Schlenk, R.F. (Richard), Taskesen, E. (Erdogan), Norden, Y. (Yvette) van, Krauter, J., Ganser, A. (Arnold), Bullinger, L. (Lars), Gaidzik, V.I. (Verena), Paschka, P. (Peter), Corbacioglu, A. (Andrea), Göhring, G. (Gudrun), Kündgen, A. (Andrea), Held, G. (Gerhard), Götze, T. (Tobias), Vellenga, E. (Edo), Kuball, J. (Jürgen), Schanz, U. (Urs), Passweg, J. (Jakob Robert), Pabst, T. (Thomas), Maertens, J. (Johan), Ossenkoppele, G.J. (Gert), Delwel, H.R. (Ruud), Döhner, H. (Hartmut), Cornelissen, J.J. (Jan), Döhner, K. (Konstanze), and Löwenberg, B. (Bob)

Abstract

The clinical value of allogeneic hematopoietic stem cell transplantation (alloHSCT) and autologous hematopoietic stem cell transplantation (autoHSCT) in the subtype of acute myeloid leukemia (AML) with double mutant CEBPA (CEBPAdm) has remained unsettled. Among 2983 patients analyzed for CEBPA mutational status (age 18-60 years) treated on 4 published Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group (HOVON/SAKK) and 3 German-Austrian AML Study Group (AMLSG) protocols (2 published, 1 registered, clinicaltrials.gov NCT00151255), 124 had AML with CEBPAdm and achieved first complete remission (CR1). Evaluation of the clinical impact of alloHSCT and autoHSCT vs chemotherapy was performed by addressing time dependency in the statistical analyses. Thirty-two patients proceeded to alloHSCT from a matched related (MRD, n 5 29) or a matched unrelated donor (MUD, n 5 3), 20 to autoHSCT in CR1 and 72 received chemotherapy. Relapse-free survival was significantly superior in patients receiving an alloHSCT or autoHSCT in CR1 as compared with chemotherapy (P <.001), whereas overall survival was not different (P <.12). Forty-five patients relapsed. Of 42 patients treated with reinduction therapy, 35 achieved a second CR (83%) and most patients (n 5 33) received an alloHSCT MRD, n 5 11; MUD, n 5 19; haplo-identical donor, n 5 3). Survival of relapsed patients measured from date of relapse was 46% after 3 years. Adult AML patients with CEBPAdm benefit from alloHSCT and autoHSCT; relapsed patients still have a favorable outcome after reinduction followed by alloHSCT.

Published
2013
Full Text
View/download PDF

39. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: A study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group

Author

Gröschel, S. (Stefan), Schlenk, R.F. (Richard), Engelmann, J., Rockova, V. (Veronika), Teleanu, V. (Veronica), Kühn, M.W.M. (Michael), Eiwen, K. (Karina), Erpelinck, C.A.J. (Claudia), Havermans, M. (Marije), Lübbert, M. (Michael), Germing, U. (Ulrich), Schmidt-Wolf, I.G.H., Beverloo, H.B. (Berna), Schuurhuis, G.J. (Gerrit Jan), Ossenkoppele, G.J. (Gert), Schlegelberger, B. (Brigitte), Verdonck, L.F. (Leo), Vellenga, E. (Edo), Verhoef, G.E.G. (Gregor), Vandenberghe, P. (Peter), Pabst, T. (Thomas), Bargetzi, M. (Mario), Krauter, J., Ganser, A. (Arnold), Valk, P.J.M. (Peter), Löwenberg, B. (Bob), Döhner, K. (Konstanze), Döhner, H. (Hartmut), Delwel, H.R. (Ruud), Gröschel, S. (Stefan), Schlenk, R.F. (Richard), Engelmann, J., Rockova, V. (Veronika), Teleanu, V. (Veronica), Kühn, M.W.M. (Michael), Eiwen, K. (Karina), Erpelinck, C.A.J. (Claudia), Havermans, M. (Marije), Lübbert, M. (Michael), Germing, U. (Ulrich), Schmidt-Wolf, I.G.H., Beverloo, H.B. (Berna), Schuurhuis, G.J. (Gerrit Jan), Ossenkoppele, G.J. (Gert), Schlegelberger, B. (Brigitte), Verdonck, L.F. (Leo), Vellenga, E. (Edo), Verhoef, G.E.G. (Gregor), Vandenberghe, P. (Peter), Pabst, T. (Thomas), Bargetzi, M. (Mario), Krauter, J., Ganser, A. (Arnold), Valk, P.J.M. (Peter), Löwenberg, B. (Bob), Döhner, K. (Konstanze), Döhner, H. (Hartmut), and Delwel, H.R. (Ruud)

Abstract

Purpose: To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements. Patients and Methods: We identified 286 patients with AML with t(11q23) enrolled onto German-Austrian Acute Myeloid Leukemia Study Group and Dutch-Belgi

Published
2013
Full Text
View/download PDF

40. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Author

Liso, A. (Arcangelo), Castiglione, F. (Filippo), Cappuccio, A. (Antonio), Stracci, F. (Fabrizio), Schlenk, R.F. (Richard), Amadori, S. (Sergio), Thiede, C. (Christian), Schnittger, S. (Susanne), Valk, P.J.M. (Peter), Döhner, K. (Konstanze), Martelli, M.F. (Massimo F.), Schaich, M. (Markus), Krauter, J., Ganser, A. (Arnold), Bolli, N. (Niccolò), Löwenberg, B. (Bob), Haferlach, T. (Torsten), Ehninger, G. (Gerhard), Mandelli, F. (Franco), Michor, F. (Franziska), Falini, B., Liso, A. (Arcangelo), Castiglione, F. (Filippo), Cappuccio, A. (Antonio), Stracci, F. (Fabrizio), Schlenk, R.F. (Richard), Amadori, S. (Sergio), Thiede, C. (Christian), Schnittger, S. (Susanne), Valk, P.J.M. (Peter), Döhner, K. (Konstanze), Martelli, M.F. (Massimo F.), Schaich, M. (Markus), Krauter, J., Ganser, A. (Arnold), Bolli, N. (Niccolò), Löwenberg, B. (Bob), Haferlach, T. (Torsten), Ehninger, G. (Gerhard), Mandelli, F. (Franco), Michor, F. (Franziska), and Falini, B.

Abstract

Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+acute myeloid leukemia) shows distinctive biological and clinical features. Experimental evidence of the oncogenic potential of the nucleophosmin mutant is, however, still lacking, and it is unclear whether other genetic lesion(s), e.g. FLT3 internal tandem duplication, cooperate with NPM1 mutations in acute myeloid leukemia development. An analysis of age-specific incidence, together with mathematical modeling of acute myeloid leukemia epidemiology, can help to uncover the number of genetic events needed to cause leukemia. We collected data on age at diagnosis of acute myeloid leukemia patients from five European Centers in Germany, The Netherlands and Italy, and determined the age-specific incidence of AML with mutated NPM1 (a total of 1,444 cases) for each country. Linear regression of the curves representing age-specific rates of diagnosis per year showed similar slopes of about 4 on a double logarithmic scale. We then adapted a previously designed mathematical model of hematopoietic tumorigenesis to analyze the age incidence of acute myeloid leukemia with mutated NPM1 and found that a one-mutation model can explain the incidence curve of this leukemia entity. This model fits with the hypothesis that NPMc+acute myeloid leukemia arises from an NPM1 mutation with haploinsufficiency of the wild-type NPM1 allele.

Published
2008
Full Text
View/download PDF

42. P-313 Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide

Author

Germing, U., primary, Giagounidis, A., additional, Büsche, G., additional, Platzbecker, U., additional, Götze, K., additional, Nolte, F., additional, Schlenk, R.F., additional, Letsch, A., additional, Ganser, A., additional, Lübbert, M., additional, Bug, G., additional, Schafhausen, P., additional, Schemenau, J., additional, and Haase, D., additional

Published
2013
Full Text
View/download PDF

44. Favorable Impact on Mainly Intermediate Cytogenetic Risk AML Can be Predicted by Gene Expression Profiling- Results of a Phase I/II Trial of Belinostat in Combination with Idarubicin in AML

Author

Bullinger, L., primary, Knudsen, S., additional, Dombret, H., additional, Dennis, M., additional, Neubauer, A., additional, Pfreundschuh, M., additional, Rossi, J., additional, Knoblauch, P., additional, Tjørnelund, J., additional, and Schlenk, R.F., additional

Published
2012
Full Text
View/download PDF

45. 119 2011-update and overview of data in the German-Austrian-Suisse MDS registry (D-A-CH MDS registry)

Author

Germing, U., primary, Giagounidis, A.A., additional, Aul, C., additional, Kündgen, A., additional, Haase, D., additional, Schanz, J., additional, Pfeilstöcker, M., additional, Nosslinger, T., additional, Platzbecker, U., additional, Götze, K., additional, Lübbert, M., additional, Blum, S., additional, Hildebrandt, B., additional, Valent, P., additional, Krieger, O., additional, Stauder, R., additional, Hofmann, W.K., additional, Braess, J., additional, Schulte, K., additional, Kreutzer, K.-A., additional, Büsche, G., additional, Stadler, M., additional, Ganser, A., additional, Schlenk, R.F., additional, Bug, G., additional, Runde, V., additional, and Gattermann, N., additional

Published
2011
Full Text
View/download PDF

46. 103 Therapy-related myeloid neoplasms following treatment with radioiodine

Author

Schroeder, T.M., primary, Kündgen, A., additional, Kröger, N., additional, Platzbecker, U., additional, Stadler, M., additional, Braulke, F., additional, Schlenk, R.F., additional, Zohren, F., additional, Haase, D., additional, Gattermann, N., additional, Haas, R., additional, Kobbe, G., additional, and Germing, U., additional

Published
2011
Full Text
View/download PDF

48. Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

Author

Schlenk, R.F., primary, Benner, A., additional, Krauter, J., additional, Büchner, T., additional, Sauerland, C., additional, Ehninger, G., additional, Schaich, M., additional, Mohr, B., additional, Niederwieser, D., additional, Krahl, R., additional, Pasold, R., additional, Döhner, K., additional, Ganser, A., additional, Döhner, H., additional, and Heil, G., additional

Published
2004
Full Text
View/download PDF

49. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.

Author

Schlenk, R.F., Hartmann, F., Hensel, M., Jung, W., Weber-Nordt, R., Gabler, A., Haas, R., Ho, A.D., Trumper, L., and Dohner, H.

Subjects
*LEUKEMIA treatment, *STEM cell transplantation
Abstract

Studies less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on the study of leukemia.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results